Experimental drug apitegromab aims to prevent muscle loss from weight-loss injections
By
Michelle Roberts
Properly proved. Has structure, has flavour, has a point.
Summary
Apitegromab, a new drug currently in clinical trials, is being developed to prevent muscle loss (often called 'Ozempic butt') caused by GLP-1 weight-loss jabs like Mounjaro. The drug works by blocking a protein involved in muscle breakdown. In a six-month obesity trial combining Mounjaro with apitegromab, participants experienced reduced muscle loss. Experts note that up to a third of weight loss from obesity jabs can come from muscle, not just fat. The manufacturer is exploring a self-injection pen format similar to existing GLP-1 injections.
Key quotes
· 3 pulledA third of the weight loss from obesity jabs can come from muscle, say experts.
Apitegromab works by blocking a protein involved in the breakdown of muscle and is also being explored as a treatment for other medical conditions affecting muscles, including spinal muscular atrophy.
The company that makes it, which funded the work, is investigating whether people could self-inject it using a special injection pen - just like GLP-1 jabs.
You might also wanna read
Semaglutide Shows Chondroprotective Effects in Osteoarthritis Through Weight Loss-Independent Metabolic Mechanism
This research article demonstrates that semaglutide, a GLP-1 receptor agonist, provides chondroprotective effects in osteoarthritis mouse mo
Study Finds GLP-1 Drugs Associated with 58% Lower Mortality in Colon Cancer Patients
A study analyzing over 6,800 colon cancer patients across University of California Health sites found that patients taking GLP-1 medications
GLP-1 Medications Show Promise for Treating Addiction Through Brain Reward Pathways
The article explores the emerging potential of GLP-1 medications like Ozempic to treat various addictions beyond their original diabetes and
newyorker.com·3mo ago
Study Finds Ozempic Does Not Slow Alzheimer's Disease Progression
Novo Nordisk announced that its popular weight-loss drug Ozempic does not slow the progression of Alzheimer's disease, based on results from
semafor.com·6mo ago
What Happens When You Stop Taking GLP-1 Weight Loss Medications
This article examines the experiences of people who stop taking GLP-1 weight loss medications (like Ozempic and Wegovy), exploring what happ
bbc.com·5mo ago
Clinical Trial Finds Ozempic Reverses Biological Age by 3.1 Years
The diabetes drug Ozempic has shown significant anti-aging effects in a clinical trial, reversing biological age by an average of 3.1 years
trial.medpath.com·10mo ago